SOX11は,BTK抵抗性マントル細胞リンパ腫における治療標的化のためのPAX5/CD19軸を通じたBCRシグナリングを調節する
Rudra Prasad Dutta1, Heng-Huan Lee2, Violetta V Leshchenko1
1Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Blood advances
|August 22, 2025
まとめ
SOX11は,BCRシグナル伝達を活性化することによって,マントル細胞リンパ腫におけるブルトンチロシンキナーゼ阻害剤耐性を駆動する. SOX11をSOX11iで標的にすることは,臨床前モデルを含む耐性MCLの治療に有望である.
科学分野:
- 血液学
- 腫瘍学
- 分子生物学
背景:
- マントル細胞リンパ腫 (MCL) は,予後が悪い攻撃的なB細胞非ホジキンリンパ腫 (NHL) である.
- ブルトンチロシンキナーゼ阻害剤 (BTKi) に対する耐性は,MCL治療における重要な臨床的課題である.
- 転写因子SOX11は,MCLの悪い結果と関連しており,BCRシグナル伝達に影響します.
研究 の 目的:
- MCLにおけるBCRシグナル伝達とBTKi抵抗を駆動するSOX11の役割を調査する.
- MCLにおけるSOX11抑制 (SOX11i) の治療の可能性を評価し,特に抵抗性のある症例において.
主な方法:
- SOX11に依存するBCR信号経路の分析
- scRNA- seqデータを用いて,イブルーチニブ耐性MCL患者のSOX11過剰発現の評価
- MCL細胞系と患者由来異種移植 (PDX) モデルにおけるSOX11iのインビトロ試験
- MCL異種移植モデルにおけるSOX11iの in vivo有効性および毒性試験
主要な成果:
- SOX11はPAX5- CD19軸の転写活性化を介してBCR信号を誘導することが判明しました.
- SOX11はイブルーチニブ耐性MCL患者で過剰発現している.
- SOX11iは,敏感で抵抗性のあるMCL細胞におけるPAX5,CD19,BCRのシグナリング成分を減少させた.
- SOX11iは,耐性MCLモデルに対して in vitroで細胞毒性を示し,有意な毒性なしに in vivoで腫瘍の成長を減少させた.
結論:
- SOX11抑制は,マンチル細胞リンパ腫の新たな治療戦略を表しています.
- SOX11をターゲットにすることで,BTKi,Venetoclax,CAR- T療法に対する耐性メカニズムを克服することができます.
- SOX11iは,MCL患者,特に耐性疾患の患者の治療結果を改善する重要なトランスレーションの可能性を持っています.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
B Cell Activation and Differentiation
5.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.6K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


